Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's President and CEO, Bo Combo, along with Chief Medical Officer Gabriel Brooks, M.D., will deliver a presentation on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
The presentation will be accessible via live webcast on the company's website's Investors section under Events, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.
Solid Biosciences (SLDB) reported Q3 2024 financial results and business updates. The company completed dosing for the first three patients in the INSPIRE DUCHENNE trial, with SGT-003 showing good tolerability and no serious adverse events. Cash position stands at $171.1 million, providing runway into 2026. Q3 net loss increased to $32.7 million ($0.79 per share) from $21.0 million year-over-year. R&D expenses rose to $27.3 million from $16.7 million, while G&A expenses increased to $7.9 million from $6.4 million. The company expanded its study protocol and plans to present initial three-patient data in Q1 2025.
Solid Biosciences (Nasdaq: SLDB) has granted 9,741 restricted stock units (RSUs) to a new employee as part of their inducement compensation package. The RSUs will vest in four equal annual installments, with full vesting occurring on the fourth anniversary of the grant date. The grant was issued under the Company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). Vesting is contingent upon the employee's continued employment with the company through each vesting date.
Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in an upcoming industry event. Chief Medical Officer Gabriel Brooks, M.D. will be part of a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on November 7, 2024, at 1:45 p.m. ET in New York. Institutional investors can arrange meetings with management through their Truist representatives.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 51,338 restricted stock units (RSUs) to three newly hired employees. These RSUs are structured to vest in four equal annual installments, with full vesting occurring on the fourth anniversary of the grant date.
The grants were made under the Company's 2024 Inducement Stock Incentive Plan and are in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows for the granting of equity as a material inducement for new employees to join the company. Continued vesting of these equity awards is contingent upon the employees' ongoing service with Solid Biosciences through each vesting date.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event will feature a fireside chat with Bo Cumbo, President and CEO, and Dr. Gabriel Brooks, Chief Medical Officer, scheduled for Monday, September 30, 2024, at 11:00 am ET.
Interested parties can access a live webcast of the fireside chat through the Events page of the Investors section on Solid Biosciences' website. A replay of the webcast will be available for 30 days after the event. Institutional investors wishing to meet with the management team during the conference are advised to contact their Chardan representatives.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's President and CEO, Bo Cumbo, along with Chief Medical Officer, Dr. Gabriel Brooks, will engage in a fireside chat on Wednesday, September 18, 2024, at 10:20 am ET.
Investors and interested parties can access a live webcast of the fireside chat through the Events page of the Investors section on the company's website. A replay of the webcast will be available for 30 days following the event. Institutional investors seeking meetings with Solid Biosciences management during the conference are advised to contact their Cantor Fitzgerald representatives.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 42,082 restricted stock units (RSUs) to three newly hired employees. These RSUs are set to vest in four equal annual installments, starting from the grant date and continuing until the fourth anniversary.
The grants were made under the company's 2024 Inducement Stock Incentive Plan and are in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows for the granting of equity as a material inducement for new employees to join the company. Vesting of these equity awards is contingent upon the employees' continued service with Solid Biosciences through each vesting date.
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines developer for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences. Bo Cumbo, President and CEO, will be involved in both events:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY: Cumbo will participate in a fireside chat on September 10, 2024, at 9:30 am ET.
2. Baird 2024 Global Healthcare Conference in New York, NY: Cumbo will present on September 11, 2024, at 12:50 pm ET.
A live webcast of the H.C. Wainwright fireside chat will be available on the company's website, with a replay archived for 30 days. Institutional investors can arrange meetings with management through their H.C. Wainwright or Baird representatives.
Solid Biosciences (NASDAQ: SLDB) reported Q2 2024 financial results and provided business updates. Key highlights include:
- Patient dosing in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for Duchenne muscular dystrophy was well-tolerated, with initial data expected Q4 2024.
- Plans to expand trial sites in the U.S., Canada, and Europe, with accelerated production of SGT-003 GMP batches.
- Targeting 3-4 IND submissions by end of 2026, including SGT-501 for CPVT in 1H 2025.
- Q2 2024 ended with $190.3 million in cash and equivalents, providing runway into 2026.
- Q2 2024 net loss was $25.1 million, or $0.61 per share.